Impact of Rapid Triplex Tests for SARS-CoV-2, Influenza, and RSV on Antibiotic Use in Respiratory Infections in Community Patients

What this Trial Is About

Respiratory infections caused by viruses such as influenza, SARS-CoV-2, and respiratory syncytial virus RSV are common, especially during winter. These illnesses often have symptoms that make it hard to tell if the infection is viral or bacterial, leading to frequent antibiotic prescriptions even when not necessary. Excessive antibiotic use contributes to bacterial resistance, a serious public health concern. This study aims to evaluate whether using a rapid test called TROD, which quickly detects these viruses, can reduce unnecessary antibiotic prescriptions in community settings during the 2025-2026 autumn-winter season. The study involves two periods for each participating doctor first, a control period where doctors treat patients without using the TROD test, and second, an intervention period where doctors use the TROD test on patients. Each period includes 10 patients who meet the eligibility criteria. The TROD test uses a nasal swab to identify SARS-CoV-2, influenza viruses, and RSV in under 15 minutes. Doctors may prescribe antibiotics based on usual practice during the control period, and with guidance from the TROD test results during the intervention period. Participants will be monitored for antibiotic prescriptions from the day of consultation to 14 days later. Researchers will collect data on antibiotic use, re-consultations, hospitalizations, and test accuracy compared to standard PCR tests. Patient characteristics and doctors practices will also be studied. The research aims to assess how the TROD test impacts antibiotic prescribing, viral infection detection, and healthcare costs, supporting efforts to reduce antibiotic resistance.

Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing